Talk:WuXi AppTec#Updates to the article

Hi, I would like to suggest some updates to the article based on the company's activities in recent years. Please add:

:*In the History section - In 2019, WuXi AppTec acquired Pharmapace, a clinical services company in San Diego, expanding WuXi AppTec's drug development and biometrics capabilities.{{Cite web|last=Adams|first=Ben|title=China's WuXi AppTec buys up U.S. Pharmapace, boosting biometrics offering|url=https://www.fiercebiotech.com/cro/china-s-wuxi-apptec-buys-up-u-s-pharmapace-boosting-biometrics-offering|date=8 May 2019|website=fiercebiotech.com}} In 2021, WuXi STA purchased a Bristol Myers Squibb drug product manufacturing facility in Switzerland, adding to WuXi STA's global services.{{Cite web|title=WuXi STA completes acquisition of Bristol Myers Squibb manufacturing facility in Switzerland|url=https://www.expresspharma.in/wuxi-sta-completes-acquisition-of-bristol-myers-squibb-manufacturing-facility-in-switzerland/|date=3 August 2021}} The same year, WuXi AppTec acquired the UK-based R&D contract company, OXGENE, and created WuXi ATU, a CDMO subsidiary focusing on cell therapy and gene therapy.{{Cite web|title=OXGENE Eyes Further Growth in Cell and Gene Therapy Services after Acquisition by WuXi AppTec|url=https://www.genengnews.com/gen-edge/oxgene-eyes-further-growth-in-cell-and-gene-therapy-services-after-acquisition-by-wuxi-apptec/|date=3 March 2021|website=genedgenews.com}} WuXi ATU opened a testing center in Philadelphia.{{Cite web|last=MacDonald|first=Gareth|title=WuXi ATU opens cell and gene therapy testing center|url=https://bioprocessintl.com/bioprocess-insider/therapeutic-class/wuxi-atu-opens-philly-cell-and-gene-therapy-testing-center/?|date=7 December 2021|website=bioprocessintl.com}} In 2022, the WuXi STA Changzhou production campus initiated oligonucleotide and peptide manufacturing to expand cell and gene therapy advancements.{{Cite web|last=Keenan|first=Joseph|title=WuXi unveils new production capabilities at Changzhou campus amid expansion push|url=https://www.fiercepharma.com/manufacturing/wuxi-unveils-oligonucleotide-peptide-production-changzhou-campus|date=7 July 2022|website=fiercepharma.com}}

{{strikethrough|Additionally, the different WuXi AppTec entities are inaccurate in the article. See this [https://www.reuters.com/article/us-china-wuxi-acquisition-idUKPEK23688220080104/ source] to explain the rename and the correct [https://www.wsj.com/market-data/quotes/HK/2269/company-people/executive-profile/15044033 entities] under the WuXi AppTec umbrella. As far as I understand, based on the guidelines, this would be an uncontroversial edit for me to do. As it is a bit labor-intensive, I am happy to go in and do it myself with the community's approval.}}

{{reflist-talk}}

Thank you! AM WuXi (talk) 18:51, 3 January 2024 (UTC)

:([https://en.wikipedia.org/w/index.php?title=User_talk%3ADrbogdan&diff=1195138887&oldid=1195084128 copied in part from the talk-page] of User:Drbogdan):

:{{reply|AM WuXi}} (and others) - Thank You for your comments - and requests - at first glance, your suggested edts seem ok - others may like to comment as well of course - hope this helps in some way - iac - Stay Safe and Healthy !! - Drbogdan (talk) 13:47, 12 January 2024 (UTC)

::{{u|Drbogdan}}, thanks for chiming in! I appreciate all feedback from the community. I posted this request several weeks ago in an effort to update and improve the existing article. If you're comfortable with it, I'd appreciate you implementing the updates. Thank you! AM WuXi (talk) 19:05, 16 January 2024 (UTC)

{{reply|AM WuXi}} (and others) - Thank You for your comments - and suggetions - I'd feel more comfortable with comments by other Editors - in order to develop a WP:CONSENSUS about this - Comments Welcome from other Editors of course - in any case - Stay Safe and Healthy - Drbogdan (talk) 21:02, 16 January 2024 (UTC)